729
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Correlations among different platelet aggregation pathways in a group of healthy volunteers

ORCID Icon, , , , , , , , , , , , , & ORCID Icon show all
Article: 2336093 | Received 12 May 2023, Accepted 21 Mar 2024, Published online: 11 Apr 2024

References

  • Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood Rev. 2021 Mar;46:100733. doi:10.1016/j.blre.2020.100733.
  • Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005 Aug;31(4):381–6. (in English). doi:10.1055/s-2005-916671.
  • Vilahur G, Gutierrez M, Arzanauskaite M, Mendieta G, Ben-Aicha S, Badimon L. Intracellular platelet signalling as a target for drug development. Vascul Pharmacol. 2018 Dec;111:22–5. doi:10.1016/j.vph.2018.08.007.
  • Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs. 2010 Oct 1;70(14):1771–83. doi:10.2165/11538060-000000000-00000.
  • Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647–57. doi:10.1111/j.1365-2125.2011.03999.x.
  • Carazo A, Hrubša M, Konečný L, Skořepa P, Paclíková M, Musil F, Karlíčková J, Javorská L, Matoušová K, Krčmová LK, et al. Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals (in English). Semin Thromb Hemost. 2022 Oct 7;49(5):488–506. doi:10.1055/s-0042-1756703.
  • Applova L, Karlíčková J, Warncke P, Macáková K, Hrubša M, Macháček M, Tvrdý V, Fischer D, Mladěnka P. 4-methylcatechol, a flavonoid metabolite with potent antiplatelet effects. Mol Nutr Food Res. 2019 Aug 7;63(20):e1900261. doi:10.1002/mnfr.201900261.
  • Badimon L, Vilahur G, Rocca B, Patrono C. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021 Jul 27;117(9):2001–15. doi:10.1093/cvr/cvab003.
  • Wilner GD, Nossel HL, Leroy EC. Aggregation of platelets by collagen (in English). J Clin Invest. 1968;47(12):2616–. doi:10.1172/Jci105944.
  • Nakashima D, Onuma T, Tanabe K, Kito Y, Uematsu K, Mizutani D, Enomoto Y, Tsujimoto M, Doi T, Matsushima-Nishiwaki R, et al. Synergistic effect of collagen and CXCL12 in the low doses on human platelet activation. PLoS One. 2020;15(10):e0241139. doi:10.1371/journal.pone.0241139.
  • Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009 May;94(5):700–11. doi:10.3324/haematol.2008.003178.
  • Coller BS, Gralnick HR. Studies on the mechanism of ristocetin-induced platelet agglutination. effects of structural modification of ristocetin and vancomycin. J Clin Invest. 1977 Aug;60(2):302–12. doi:10.1172/JCI108778.
  • Rao GHR, White JG. Platelet activating factor (paf) causes human-platelet aggregation through the mechanism of membrane modulation (in English). Prosta Leukotr Med. 1982;9(4):459–72. doi:10.1016/0262-1746(82)90102-0.
  • Lordan R, Tsoupras A, Zabetakis I. Phospholipids of animal and marine origin: structure, function, and anti-inflammatory properties. Molecules. 2017 Nov 14;22(11):1964. doi:10.3390/molecules22111964.
  • Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M, et al. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res. 2016 Feb;138:63–8. (in English). doi10.1016/j.thromres.2015.10.038.
  • Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR. Platelet aggregation in whole blood determined using the ultra-flo 100 platelet counter. Thromb Haemost. 1982 Dec;48(3):327–9. doi:10.1055/s-0038-1657292.
  • Ranger A, Gaspar M, Elkhatteb A, Jackson T, Fox S, Aw TC, Vipond L, Cotterill J, Ghori A, Laffan M, et al. The heparin-von Willebrand factor interaction and conventional tests of haemostasis – the challenges in predicting bleeding in cardiopulmonary bypass. Br J Haematol. 2021 Mar;192(6):1073–81. doi:10.1111/bjh.17263.
  • Gelbenegger G, Jilma B. Clinical pharmacology of antiplatelet drugs. Expert Rev Clin Pharmacol. 2022 Oct;15(10):1177–97. doi:10.1080/17512433.2022.2121702.
  • Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9(3):552–61. doi:10.1111/j.1538-7836.2010.04160.x.